Following on from information provided to NICE by the company in October 2021 the appraisal of Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3809 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in October 2021 the appraisal of Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 October 2021 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. For information, the company have announced that they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 12 March 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. |
| 04 February 2021 - 04 March 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 03 March 2020 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual